PUBLISHER: GlobalData | PRODUCT CODE: 1458557
PUBLISHER: GlobalData | PRODUCT CODE: 1458557
This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.
Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being a rare cancer, ovarian cancer is a blockbuster market and is expected to grow from sales of $3.3 billion in 2022 to $4.1 billion in 2032 at a compound annual growth rate (CAGR) of 2.0%. Ovarian cancer patients generally respond well to platinum-based chemotherapy and achieve complete remission in the initial setting. However, the risk of recurrence for patients with residual disease is high. Additionally, the rapid emergence of chemotherapy resistance is observed. Currently, the standard treatment for platinum-resistant patients is sequential non-platinum treatment with either monotherapy or combination treatment with targeted therapy (bevacizumab) or cytotoxic agents (taxanes, gemcitabine, pegylated liposomal doxorubicin, or topotecan).There are several unmet needs in Ovarian Cancer that call for improved front-line treatment options and alternative options for platinum-resistant patients for extending overall survival in patients.
Major drivers of growth in the Ovarian Cancer market across the 7MM over the forecast period include the following:
chemotherapies.
Major barriers to growth in the Ovarian Cancer market across the 7MM over the forecast period include the following:
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer.
These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.
Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being a rare cancer, ovarian cancer is a blockbuster market and is expected to grow from sales of $3.3 billion in 2022 to $4.1 billion in 2032 at a compound annual growth rate (CAGR) of 2.0%.
Overview of Ovarian Cancer, including epidemiology, symptoms, diagnosis, and disease management.
Annualized Ovarian Cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Ovarian Cancer therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Ovarian Cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
Analysis of the current and future market competition in the global Ovarian Cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global Ovarian Cancer therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Ovarian Cancer therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships